Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.33 |
| ▸ | IL6 | P05231 | 11/20 | 0.33 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26362151 | 0.89 | TLR7 (0.36) | TLR7IL6MAP1LC3B | |
| SCHEMBL26348221 | 0.88 | TLR7 (0.41) | TLR7IL6 | |
| SCHEMBL29034538 | 0.78 | TLR7 (0.43) | TLR7IL6BCHEACHE | |
| SCHEMBL26355513 | 0.78 | TLR7 (0.43) | TLR7IL6BCHEACHE | |
| SCHEMBL26355527 | 0.78 | TLR7 (0.43) | TLR7IL6BCHEACHE | |
| SCHEMBL26348223 | 0.78 | TLR7 (0.42) | TLR7IL6 | |
| SCHEMBL26348222 | 0.77 | TLR7 (0.45) | TLR7IL6 | |
| SCHEMBL26348220 | 0.76 | TLR7 (0.52) | TLR7IL6 | |
| SCHEMBL26347255 | 0.75 | TLR7 (0.53) | TLR7IL6 | |
| SCHEMBL26360251 | 0.74 | TLR7 (0.44) | TLR7IL6BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TLR7 4/4885IL6 1194/4885MAP1LC3B 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.